Marc Rubin

Filings by Marc Rubin span 3 companies, the busiest being Galectin Therapeutics Inc, Titan Pharmaceuticals Inc and Curis Inc. Over a trading history stretching from 5 February 2008 to 20 March 2026, the count stands at 35 filings.

On the open market, the record shows 18 purchases worth €364k and 6 sales worth €659k. Taken together, the sales exceed the purchases by €295k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 6 share grants and 4 option exercises.

In size, the median ticket on the buying side is €14k. Of 4 purchases, 4 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. Looking at 5 purchases old enough to measure, the stock rose over the following 90 days in 60% of cases; the median change was +46.9%. These figures describe past trades and do not predict future prices.

Most recently, on 23 March 2026, the filings show a transaction in Curis Inc. The clock since the last published purchase (25 September 2018) now reads 2,950 days. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.